Recombinant Human Steroid 17-Alpha-Hydroxylase/17,20 Lyase (CYP17A1) Protein (His)

Name: Recombinant Human Steroid 17-Alpha-Hydroxylase/17,20 Lyase (CYP17A1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-08170P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Steroid 17-Alpha-Hydroxylase/17,20 Lyase (CYP17A1) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P05093
Target Symbol	CYP17A1
Synonyms	20 lyase; CP17A_HUMAN; CPT7; CYP17; CYP17A1; CYPXVII; Cytochrome P450 17A1; Cytochrome P450 family 17; Cytochrome P450 family 17 subfamily A polypeptide 1; Cytochrome p450 subfamily XVII (steroid 17 alpha hydroxylase) adrenal hyperplasia; Cytochrome p450 XVIIA1; Cytochrome P450-C17; Cytochrome P450c17; OTTHUMP00000020382; P450 C17; P450c17; S17AH; Steroid 17 alpha hydroxylase/17,20 lyase; Steroid 17 alpha monooxygenase; Steroid 17-alpha-hydroxylase/17; Steroid 17-alpha-monooxygenase
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	GAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST
Expression Range	24-508aa
Protein Length	Partial
Mol. Weight	58.6kDa
Research Area	Cardiovascular
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (Probable). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione. Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA. Also 16-alpha hydroxylates androgens, relevant for estriol synthesis. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase).
Subcellular Location	Endoplasmic reticulum membrane. Microsome membrane.
Protein Families	Cytochrome P450 family
Database References	HGNC: 2593 OMIM: 202110 KEGG: hsa:1586 STRING: 9606.ENSP00000358903 UniGene: PMID: 29338791 - 34T>C polymorphism in CYP17A1 is associated with polycystic ovary syndrome. PMID: 29564739 We present one novel and one ultra rare gene variant with 17-OH deficiency, both described for the first time PMID: 29595516 identified a novel compound heterozygous CYP17A1 mutation His373Tyr (c.1117C>T) in a patient with 17alpha-hydroxylase/17,20-lyase deficiency. PMID: 29278670 the rs11191548 CYP17A1 gene mutation was associated with hypertension and the serum 25(OH) D levels in Han Chinese PMID: 29556032 T allele of rs743572 T polymorphism might predict high susceptibility to endometriosis, but it had no significant influence on characteristics and severity of endometriosis. PMID: 29995789 A polymorphism in the CYP17A1 gene was associated with the response to steroidogenesis inhibitors in Cushing's syndrome. PMID: 28665508 A single-point mutation at asparagine 202 in the active site pocket of CYP17A1, even when far from the heme, has profound effects on steroidogenic selectivity in androgen biosynthesis. In the mutant the 17alpha alcohol of OHPROG forms a H-bond with the proximal rather than terminal oxygen of the oxy-ferrous complex.When OHPREG was a substrate, the mutant was found to have weak H-bonding interaction with the proximal ox... PMID: 29283561 VT-464 reduces androgen receptor (AR) signaling more effectively than abiraterone in cultured PCa cells expressing T877A AR mutant PMID: 27748439 To our knowledge, this is the first study showing that the CYP17 T-34C and CYP19 T PMID: 29285776 the CYP17A1 polymorphisms could be a genetic risk factor for essential hypertension among the Yunnan Han Chinese population. PMID: 28537227 one CYP17A1 mutation (p.Arg362Cys) may share a common ancestry in Brazilian and present Spanish patients, while p.Trp406Arg may have arisen separately. PMID: 28376482 the CYP17CC genotype was significantly associated with developmental stuttering PMID: 28992603 A novel nonsense mutation in androgen receptor confers resistance to CYP17A1 inhibitor treatment in prostate cancer. PMID: 28036278 The mechanism of action, the efficacy and the clinical potential of CYP17A1 inhibitors in prostate cancer are also summarized. [review] PMID: 29372682 through mouse-to-human search and validation, we found that CYP17A1 is overexpressed in hepatocellular carcinomas and it has great potentiality as a noninvasive marker for hepatocellular carcinoma detection PMID: 27339169 Nominally significant parental genetic effects were found between the SNPs rs11191548 (CYP17A1) (paternal, beta = 2.78+/-1.49, P = 6.1x10-2 for SBP and beta = 3.60+/-1.24, P = 3.7x10-3 for DBP), rs17367504 (MTHFR) (paternal, beta = 2.42+/-0.93, P = 9.3x10-3 for SBP and beta = 1.89+/-0.80, P = 1.8x10-2 for DBP and maternal, beta = -1.32+/-0.60, P = 2.9x10-2 and beta = -1.97+/-0.77, P = 1.0x10-2, for SBP and DBP respecti... PMID: 29045471 Wild-type CYP17 allele when combined with LOH/MSI in steroid metabolism genes may play a role in ER and/or PR negative breast cancers. PMID: 28692125 Data suggest CYP17A1, with electron donor NADPH-P450 reductase, is inherently distributive enzyme but that some processivity is present; some 17alpha-hydroxy pregnenolone formed does not dissociate from CYP17A1 before conversion to dehydroepiandrosterone; CYP5A does not enhance reaction by decreasing k(off) of ligands of CYP17A1. (CYP17A1 = cytochrome P450, family 17, subfamily A, polypeptide 1; CYP5A = cytochrome b5) PMID: 28684414 we identified a novel (K144del) and a widely reported (Y329 fs) heterozygous mutations of CYP17A1 gene from a 17OHD patient. Haplotyping analysis showed the common mutation Y329 fs in China came from the same ancestor, which explains the reason that 17OHD was the second cause of congenital adrenal hyperplasia in China. PMID: 27150612 The activities of P450 17A1 are regulated by cyt b5 that enhances the 17,20-lyase reaction by promoting the coupling of P450 17A1 and cytochrome P450 reductase (CPR), allosterically. Cyt b5 can also act as an electron donor to enhance the 16-ene-synthase activity of human P450 17A1. PMID: 26976652 The results showed that CYP17A1 gene was not conclusively linked to either Insulin resistance (IR) or its associated increased androgen secretion in non-obese women with polycystic ovarian syndrome (PCOS). We propose that an increased sensitivity of insulin on the ovarian cells may be the predominant reason for the clinical effects and symptoms of androgen excess observed in non-obese PCOS patients in our region. PMID: 27748298 CYP17A1 defects were associated with amenorrhea, ovarian macrocysts and the diagnosis of 46, XX syndrome. PMID: 26920256 The discovery of these specific drug actions on steroidogenic enzyme activities would be valuable for understanding the regulation of androgens. PMID: 27395338 For the naturally occurring P450 17A1 mutations E305G and R347H, which impair 17,20-lyase activity, cytochrome b5 failed to rescue the poor coupling with 17-hydroxypregnenolone (2-4%). When the conserved active-site threonine was mutated to alanine (T306A), both the activity and coupling were markedly decreased with all substrates. PMID: 27426448 Mechanism of 17alpha,20-Lyase and New Hydroxylation Reactions of Human Cytochrome P450 17A1: 18O LABELING AND OXYGEN SURROGATE EVIDENCE FOR A ROLE OF A PERFERRYL OXYGEN. PMID: 27339894 The intensity of menopausal symptoms related to mood is higher among postmenopausal women presenting the GG genotype of the rs743572 polymorphism of the CYP17 A1 gene. PMID: 27117436 The analyzed polymorphisms in CYP17A1 do not seem to be correlated with clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. PMID: 26954071 The common genetic variant rs2486758 in CYP17A1 was negatively associated with a biochemical response to and time to biochemical progression in patients treatment on abiraterone acetate and prednisone within metastatic castration-resistant prostate cancer. PMID: 27409606 CYP17 Gene Polymorphism is not associated with Breast Cancer. PMID: 27165202 CYP17 Gene Polymorphism is associated with Pancreatic Cancer. PMID: 27165211 CYP17 gene might be a risk factor for prostate cancer in males of advanced age. PMID: 26985923 Results show high level of CYP17A1 mRNA level in postmenopausal invasive ductal cancer which correlates with tumor prognosis. PMID: 27365044 No significant association between CYP17-34T/C polymorphism and insulin resistance was found in Thai polycystic ovary syndrome women, although the A2/X genotype group was statistically significantly younger than the A1/A1 genotype group. PMID: 26096606 the meta-analysis suggested that the CYP17 gene polymorphism was not associated with endometriosis risk. PMID: 25511200 Low apparent CYP17A1 activity is associated with elevated daytime ambulatory blood pressure when salt intake is high. CYP17A1 activity is heritable and diminished in the elderly. PMID: 26297028 The present meta-analysis confirmed the significant association between a polymorphism of the CYP17A1 gene and hypertension susceptibility. PMID: 25990650 CYP17A1 rs3824755 and rs743572 are associated with Alzheimer's disease in the Chinese Han population and act in combination with APOE e4. PMID: 26940238 Data indicate that cytochrome P450 17A1 (CYP17A1) first catalyzes pregnenolone (PREG) and then converts the 17-hydroxypregnenolone initial product to dehydroepiandrosterone, a process representing the first committed step in the biosynthesis of androgens. PMID: 26668369 Polymorphism single nucleotide of CYP17A1 gene is implicated to the development of high blood pressure. PMID: 26902494 The FMN domain outcompetes b5 for binding to CYP17A1 in the three-component system PMID: 26719338 Our study suggests no strong association between the CYP17A1 T27C and LEP -2548G>A polymorphisms and the incidence of breast cancer in Turkish women. PMID: 26407154 Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1 PMID: 26973185 The compound heterozygous mutation of p. Thr101Ilefs*2 and p. Thr306Ale is a new gene mutation of 17alpha-hydroxylase/17, 20-lyase deficiency. PMID: 26345865 genetic variants in the androgen-related genes CYP17A1 and JMJD1C might be associated with risk of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). PMID: 26414697 Thus, CYP17A1 may contribute to cardiac hypertrophy in this clinical condition. PMID: 26263970 Cytochrome-17 Gene Polymorphism is associated with Risk of Gall Bladder Stones and Cancer. PMID: 26225710 CYP17A1 mutation is associated with 17alpha-Hydroxylase/17-20 lyase deficiency leading to congenital adrenal hyperplasia. PMID: 25719302 Higher organochlorine pesticide levels and the A1A1 genotype of CYP17A1 in pregnant women may be considered as important aetiological factors in idiopathic small for gestational age. PMID: 25064838 The aim of the present study was to assess the association between CYP17A1 gene polymorphism and coronary artery disease in a Chinese Uygur population. PMID: 25592814

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.